Faculty

Institution

Unit

Venue

Daniel Jonathan Chandra, M.D.

Assistant Professor of OHSU Knight Cancer Institute School of Medicine

Oregon Health & Science University

Affiliations

Center For Hematologic Malignancies

OHSU School of Medicine

Department Of Medicine

Department of Medicine

Division of Hematology & Medical Oncology

Department Of Medicine

Hematology and Medical Oncology

Oregon Health & Science University

Daniel Jonathan Chandra, M.d. is currently serving as a Center For Hematologic Malignancies Assistant Professor of OHSU Knight Cancer Institute School of Medicine at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Daniel Jonathan Chandra, M.D.

Oregon Health & Science University

Assistant Professor of OHSU Knight Cancer Institute School of Medicine

You can click a keyword to filter the displayed items

medicine hematology immunology clinical transplantation bone marrow transplantation transplantation medicine leukemia hematological malignancies myeloid neoplasia stem cell transplantation pathology cell biology oncology cell transplantation experimental medicine cell research pharmacotherapy post-transplant cyclophosphamide cancer research immunotherapy cancer cells transplantation proceeding graft survival allogeneic transplant outcomes cancer immunotherapy molecular medicine drug resistance cell signaling molecular diagnostics molecular cell biology cardiovascular research cardiovascular interventions health technology medical internet research medicinal research prognosis drug resistance analysis cardiovascular toxicity cardiac pathologies immunosuppressive therapy cell replacement therapies metronomic chemotherapy steroid metabolism telecare telepresence blood donation innate immune system immunopathology acute myeloid leukemia who 5th practical considerations aml patients treated prognostic significance abstract 721 fludarabine/melphalan conditioning ventricular dysfunction interferon-γ signaling undergoing allogeneic transplantation melphalan conditioning comparable outcomes comparative outcomes mg/kg2 vs 100

Notable Scholarly Works

Notable Federal Grants

Collaborators

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

health sciencesmedicinecritical careclinical transplantationorgan transplantationstem cell transplantationtransplantation medicinecell transplantationpost-transplant cyclophosphamideallogeneic transplant outcomesbone marrow transplantationgraft survivalhematology

Allogeneic Transplant Outcomes in Patients Aged ≥70 vs 70 With Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

medicineclinical transplantationcritical careorgan transplantationstem cell transplantationtransplantation medicinecell transplantationpost-transplant cyclophosphamideallogeneic transplant outcomesbone marrow transplantationhematologyfludarabine/melphalan conditioning

Comparative Outcomes of 80 Mg/Kg2 vs 100 Mg/Kg 2 Post-Transplant Cyclophosphamide Following Flumel100 Conditioning in Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy (2026)

clinical trialsmedicineclinical transplantationtransplantation proceedinghaematopoiesisstem cell transplantationtransplantation medicinecomparative outcomescell transplantationimmunologybone marrow transplantationmg/kg2 vs 100hematologymg/kg 2

Abstract 721: The Role of Ncam1(Cd56) in Mediating Venetoclax Resistance. Cancer Research (2025)

abstract 721molecular cell biologymolecular medicinedrug resistancecell signalingcytoskeletonimmunologycell researchcell biologydrug resistance analysistherapeutic targets

Comparable Outcomes in Patients Aged ≥70 vs. Lt;70 Undergoing Allogeneic Transplantation With Fludarabine and Melphalan Conditioning and Post-Transplant Cyclophosphamide. Blood (2025)

outcomes researchmedicineclinical transplantationcritical careorgan transplantationtransplantation medicineundergoing allogeneic transplantationpharmacotherapybone marrow transplantationgraft survivalhematologymelphalan conditioningcomparable outcomes

Comparison of 80 Mg/Kg vs. 100 Mg/Kg Post-Transplant Cyclophosphamide Dose With Flu/Mel and Allogeneic Transplant: Less is Not More. Blood (2025)

pharmacologyclinical trialsmedicineclinical transplantationtransplantation proceedingorgan transplantationtransplantation medicineimmunosuppressive therapypharmacotherapyclinical researchbone marrow transplantationhematologyallogeneic transplant

Flumel100 With Post-Transplant Cyclophosphamide: A Safe and Effective Regimen for Patients Aged ≥75 Years With Mds and Aml. Blood (2025)

pharmacologymedicineclinical transplantationorgan transplantationoncologytransplantation medicinepharmacotherapyeffective regimenpost-transplant cyclophosphamidetranslational medicinebone marrow transplantationcell replacement therapiesmetronomic chemotherapy

Telehealth Based Virtual Consult Visits and In-Person Consult Visits Provide Comparable Time to Hla-Typing and Preliminary Donor Search in Patients Referred for Allogeneic Hematopoietic Cell Transplantation. Blood (2025)

digital healthhealth technologymedicineclinical transplantationtelehealthvirtual consult visitscomparable timestem cell transplantationtransplantation medicinetelecaretelepresencepreliminary donor searchmedical internet researchblood donationbone marrow transplantationfamily medicinehematology

The Aryl Hydrocarbon Receptor is Associated With Monocytic Aml and Innate Immune Resistance Reversible With an Ahr Inhibitor. Frontiers in Immunology (2025)

allergyimmunity (medicine)immune resistance reversibleinnate immune systemaryl hydrocarbon receptorimmunologymedicinal researchimmunopathologyimmune responsesexperimental medicineahr inhibitor

The Dysregulated Cytokine Microenvironment of Venetoclax-Resistant Acute Myeloid Leukemia is Associated With Natural Killer Cell Suppression. Transplantation and Cellular Therapy (2025)

immune responseshematologycell deathhematological malignanciesleukemiadysregulated cytokine microenvironmentimmunologycell biologymyeloid neoplasiaexperimental medicine

1
2
10 / page

Daniel Jonathan Chandra, M.D.

Assistant Professor of OHSU Knight Cancer Institute School of Medicine

Oregon Health & Science University

Affiliations

Center For Hematologic Malignancies

OHSU School of Medicine

Department Of Medicine

Department of Medicine

Division of Hematology & Medical Oncology

Department Of Medicine

Hematology and Medical Oncology

Oregon Health & Science University

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Daniel Jonathan Chandra, M.D.

Oregon Health & Science University

Assistant Professor of OHSU Knight Cancer Institute School of Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

Allogeneic Transplant Outcomes in Patients Aged ≥70 vs 70 With Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy (2026)

Abstract 721: The Role of Ncam1(Cd56) in Mediating Venetoclax Resistance. Cancer Research (2025)

abstract 721molecular cell biologymolecular medicinedrug resistancecell signalingcytoskeletonimmunologycell researchcell biologydrug resistance analysistherapeutic targets

Comparable Outcomes in Patients Aged ≥70 vs. Lt;70 Undergoing Allogeneic Transplantation With Fludarabine and Melphalan Conditioning and Post-Transplant Cyclophosphamide. Blood (2025)

Comparison of 80 Mg/Kg vs. 100 Mg/Kg Post-Transplant Cyclophosphamide Dose With Flu/Mel and Allogeneic Transplant: Less is Not More. Blood (2025)

Flumel100 With Post-Transplant Cyclophosphamide: A Safe and Effective Regimen for Patients Aged ≥75 Years With Mds and Aml. Blood (2025)

The Aryl Hydrocarbon Receptor is Associated With Monocytic Aml and Innate Immune Resistance Reversible With an Ahr Inhibitor. Frontiers in Immunology (2025)

allergyimmunity (medicine)immune resistance reversibleinnate immune systemaryl hydrocarbon receptorimmunologymedicinal researchimmunopathologyimmune responsesexperimental medicineahr inhibitor

The Dysregulated Cytokine Microenvironment of Venetoclax-Resistant Acute Myeloid Leukemia is Associated With Natural Killer Cell Suppression. Transplantation and Cellular Therapy (2025)

immune responseshematologycell deathhematological malignanciesleukemiadysregulated cytokine microenvironmentimmunologycell biologymyeloid neoplasiaexperimental medicine

1
2
10 / page